Nanologica AB (publ) (NICA.ST)
SEK 1.21
(-1.63%)
SEK 1.21
(-1.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 77.42 Million SEK | -49.89% |
| 2022 | 154.51 Million SEK | 57.16% |
| 2021 | 98.31 Million SEK | -32.82% |
| 2020 | 146.34 Million SEK | 246.08% |
| 2019 | 42.28 Million SEK | 23.18% |
| 2018 | 34.32 Million SEK | 32.48% |
| 2017 | 25.91 Million SEK | -18.69% |
| 2016 | 31.87 Million SEK | -2.74% |
| 2015 | 32.76 Million SEK | 67.22% |
| 2014 | 19.59 Million SEK | 40.98% |
| 2013 | 13.89 Million SEK | 114.36% |
| 2012 | 6.48 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 107.92 Million SEK | 39.38% |
| 2024 Q2 | 106.21 Million SEK | -1.58% |
| 2023 Q1 | 146.79 Million SEK | -5.0% |
| 2023 Q3 | 111.09 Million SEK | -10.67% |
| 2023 Q2 | 124.36 Million SEK | -15.28% |
| 2023 Q4 | 77.42 Million SEK | -30.3% |
| 2023 FY | 77.42 Million SEK | -49.89% |
| 2022 Q1 | 90.38 Million SEK | -8.06% |
| 2022 Q4 | 154.51 Million SEK | 68.42% |
| 2022 FY | 154.51 Million SEK | 57.16% |
| 2022 Q3 | 91.74 Million SEK | -19.56% |
| 2022 Q2 | 114.05 Million SEK | 26.18% |
| 2021 Q1 | 138.54 Million SEK | -5.33% |
| 2021 Q4 | 98.31 Million SEK | -14.92% |
| 2021 Q3 | 115.55 Million SEK | -11.97% |
| 2021 FY | 98.31 Million SEK | -32.82% |
| 2021 Q2 | 131.27 Million SEK | -5.25% |
| 2020 Q4 | 146.34 Million SEK | 4.51% |
| 2020 Q3 | 140.02 Million SEK | -8.28% |
| 2020 Q2 | 152.67 Million SEK | 227.13% |
| 2020 FY | 146.34 Million SEK | 246.08% |
| 2020 Q1 | 46.67 Million SEK | 10.37% |
| 2019 Q3 | 42.62 Million SEK | 81.87% |
| 2019 FY | 42.28 Million SEK | 23.18% |
| 2019 Q4 | 42.28 Million SEK | -0.79% |
| 2019 Q2 | 23.43 Million SEK | -24.46% |
| 2019 Q1 | 31.02 Million SEK | -9.63% |
| 2018 Q4 | 34.32 Million SEK | -8.96% |
| 2018 FY | 34.32 Million SEK | 32.48% |
| 2018 Q3 | 37.7 Million SEK | -12.54% |
| 2018 Q2 | 43.11 Million SEK | 120.27% |
| 2018 Q1 | 19.57 Million SEK | -24.47% |
| 2017 FY | 25.91 Million SEK | -18.69% |
| 2017 Q1 | 23.87 Million SEK | -25.08% |
| 2017 Q4 | 25.91 Million SEK | 32.48% |
| 2017 Q2 | 25.37 Million SEK | 6.29% |
| 2017 Q3 | 19.56 Million SEK | -22.92% |
| 2016 Q2 | 23.97 Million SEK | -8.44% |
| 2016 Q3 | 40.28 Million SEK | 68.02% |
| 2016 FY | 31.87 Million SEK | -2.74% |
| 2016 Q1 | 26.18 Million SEK | -20.09% |
| 2016 Q4 | 31.87 Million SEK | -20.88% |
| 2015 Q4 | 32.76 Million SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q2 | 13.2 Million SEK | 0.0% |
| 2015 FY | 32.76 Million SEK | 67.22% |
| 2014 FY | 19.59 Million SEK | 40.98% |
| 2014 Q3 | 19.59 Million SEK | 0.0% |
| 2014 Q4 | 19.59 Million SEK | 0.0% |
| 2013 FY | 13.89 Million SEK | 114.36% |
| 2012 FY | 6.48 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Active Biotech AB (publ) | 44 Million SEK | -75.975% |
| Biovica International AB (publ) | 131.4 Million SEK | 41.077% |
| Cantargia AB (publ) | 223.71 Million SEK | 65.389% |
| CombiGene AB (publ) | 120.61 Million SEK | 35.803% |
| Cyxone AB (publ) | 43.65 Million SEK | -77.366% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -171.604% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -156.617% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 1.605% |
| Fluicell AB (publ) | 9.34 Million SEK | -729.004% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 77.961% |
| Mendus AB (publ) | 755.95 Million SEK | 89.757% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 44.928% |
| I-Tech AB | 152.44 Million SEK | 49.208% |
| Intervacc AB (publ) | 259.61 Million SEK | 70.175% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -130.43% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 72.222% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -286.353% |
| OncoZenge AB (publ) | 20.34 Million SEK | -280.674% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -24.131% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 88.152% |
| Lipum AB (publ) | 12.11 Million SEK | -539.381% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 34.631% |
| Ziccum AB (publ) | 14.97 Million SEK | -417.159% |
| BioArctic AB (publ) | 1.18 Billion SEK | 93.472% |
| Genovis AB (publ.) | 288.85 Million SEK | 73.195% |
| Camurus AB (publ) | 1.9 Billion SEK | 95.941% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 56.285% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -24.58% |
| Aptahem AB (publ) | 63.02 Million SEK | -22.855% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 84.397% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 89.882% |
| Kancera AB (publ) | 65.64 Million SEK | -17.955% |
| Saniona AB (publ) | 64.14 Million SEK | -20.713% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -46.134% |
| AcouSort AB (publ) | 34.51 Million SEK | -124.347% |
| Xintela AB (publ) | 18.39 Million SEK | -320.924% |
| Abliva AB (publ) | 87.49 Million SEK | 11.509% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 93.847% |
| Amniotics AB (publ) | 26.08 Million SEK | -196.822% |
| 2cureX AB (publ) | 16.62 Million SEK | -365.738% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1174.132% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 95.926% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 92.394% |
| Biosergen AB | 7.2 Million SEK | -975.253% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -84.535% |
| Corline Biomedical AB | 100.1 Million SEK | 22.652% |
| NextCell Pharma AB | 81.28 Million SEK | 4.747% |
| LIDDS AB (publ) | 17.65 Million SEK | -338.567% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 89.815% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 94.47% |
| SynAct Pharma AB | 228.01 Million SEK | 66.043% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -189.314% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -256.768% |
| Alzinova AB (publ) | 123.18 Million SEK | 37.146% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 11.075% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 67.518% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -815.778% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 9.15% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -420.741% |
| Simris Alg AB (publ) | 174.55 Million SEK | 55.641% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 64.325% |